United Therapeutics Corporation (NASDAQ:UTHR) is among the top gainers of the stock market today, skyrocketing 3.53% or (3.13 points) to $91.77 from its previous close of $88.64. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 321924 contracts so far this session. UTHR shares had a relatively better volume day versus average trading capacity of 514.3 thousand shares, but with a 43.04 million float and a -8.32% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for UTHR stock indicates that the average analyst price target is $122 per share. This means the stock has a potential increase of 32.94% from where the UTHR share price has been trading recently which is between $88.2632 and $89.96. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $90.
The shorts are running away from United Therapeutics Corporation (UTHR) stock. The latest set of short interest data was released on 30 April 2019, and the numbers show a drop in short interest in UTHR shares. While short interest still represents only 9.05% of UTHR’s float, the number of shares shorted have fallen by -38866. The number of shares shorted fell to 3855939 shares, down from 3894805 shares during the preceding fortnight. With average daily trading volumes at 574628 shares, days to cover decreased to about 9.183067 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Arena Pharmaceuticals’ (ARNA) Loss Widens in Q1 But Stock Up” and dated May 09, 2019.
During the recent trading session for United Therapeutics Corporation (NASDAQ:UTHR), the company witnessed their stock drop by $-2.78 over a week and tumble down $-8.48 from the price 20 days ago. When compared to their established 52-week high of $130, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 08/17/18. The recent low of $88.23 stood for a -29.41% since 05/17/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.04 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for United Therapeutics Corporation, the two-week RSI stands at 33.76. This figure suggests that UTHR stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current UTHR readings is similarly very revealing as it has a stochastic reading of 9.64% at this stage. This figure means that UTHR share price today is being overbought.
Technical chart claims that United Therapeutics Corporation (UTHR) would settle between $89.65/share to $90.65/share level. However, if the stock price goes below the $87.95 mark, then the market for United Therapeutics Corporation becomes much weaker. If that happens, the stock price might even plunge as low as $87.26 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -3.12. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at UBS raised their recommendation on shares of UTHR from Sell to Neutral in their opinion released on May 17. Credit Suisse analysts bumped their rating on United Therapeutics Corporation (NASDAQ:UTHR) stock from Underperform to Neutral in a separate flash note issued to investors on May 09. Analysts at Standpoint Research released an upgrade from Hold to Buy for the stock, in a research note that dated back to October 12.
UTHR equity has an average rating of 3.17, with the figure leaning towards a bullish end. 12 analysts who tracked the company were contacted by Reuters. Amongst them, 6 rated the stock as a hold while the remaining 6 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while others rated it as a sell. 2 analysts rated United Therapeutics Corporation (NASDAQ:UTHR) as a buy or a strong buy while 4 advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, UTHR stock price is currently trading at 10.66X forward 12-month Consensus EPS estimates, and its P/S ratio is 2.43 while for the average stock in the same group, the multiple is 42.11.
United Therapeutics Corporation (UTHR)’s current-quarter revenues are projected to climb by nearly -25.36% to hit $331780, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over -19.05% from $1.63 billion to a noteworthy $1.32 billion. At the other end of the current quarter income statement, United Therapeutics Corporation is expected to see its adjusted earnings surge by roughly -44.95% to hit $2.4 per share. For the fiscal year, UTHR’s earnings are projected to climb by roughly -132.75% to hit $-5.03 per share.